bosentan anhydrous has been researched along with losartan potassium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brochu, E; Grose, JH; Kingma, I; Lacasse, S; Larivière, R; Lebel, M | 1 |
| Hussar, DA | 1 |
| Hampton, MB; Keenan, JI; Kerkelä, R; Pemberton, CJ; Piuhola, J; Richards, AM | 1 |
| Barhoumi, T; Berthelot, A; Jallat, I; Laurant, P | 1 |
5 other study(ies) available for bosentan anhydrous and losartan potassium
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure.
Topics: Animals; Blood Pressure; Bosentan; Creatinine; Endothelin Receptor Antagonists; Endothelin-1; Erythropoietin; Hematocrit; Humans; Hypertension; Kidney Failure, Chronic; Male; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Recombinant Proteins; Sulfonamides | 1999 |
New drugs 2002, part III.
Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid | 2002 |
Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury.
Topics: Animals; Apoptosis; Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Erythropoietin; Heart; Humans; Janus Kinase 2; Male; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Natriuretic Peptide, Brain; Perfusion; Phosphorylation; Rats; Rats, Sprague-Dawley; Recombinant Proteins; STAT3 Transcription Factor; Stimulation, Chemical; Sulfonamides | 2008 |
Human recombinant erythropoietin alters the flow-dependent vasodilatation of in vitro perfused rat mesenteric arteries with unbalanced endothelial endothelin-1 / nitric oxide ratio.
Topics: Animals; Antihypertensive Agents; Bosentan; Cell Line; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Erythropoietin; Hematinics; Humans; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2011 |